COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/VALSARTAN IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN SPAIN

Author(s)

Lacasa C1, Obradors M1, Figueras M1, Pérez-Alcántara F2, Brosa M3
1Novartis Farmaceutica S.A., Barcelona, Spain, 2OBLIKUE Consulting, Barcelona, Spain, 3Oblikue Consulting, Barcelona, Spain

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCV81

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×